Treatment of Schizophrenic Patients With Ziprasidone

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Usual clinical practice of physician

Exclusion Criteria:

• None